United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$199Mraised across 6 rounds since 2010, from 7 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Reported by HealthCare Royalty and 1 other
Source recordedSEC filing: $9.0M sold, first sale Nov 2022
SR One
Osage University Partners
Atlas
The Kraft Group
Lundbeckfonden VenturesReported by FinSMEsSEC filing: $43M sold, first sale Mar 2017
Atlas VentureSR One
GlaxoSmithKline
New England PatriotsFrom a historical funding record
From Spero Therapeutics's own website and the SEC filings it signed: 10 on the team.
On the board, as filediJohn C. PottageKathleen C. TregoningMilind DeshpandePatrick E. VinkScott C. Jackson
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
SR One
National Science Foundation
RA Capital ManagementAtlas Partner
Google VenturesAtlas VentureOsage University PartnersPartners HealthCare InnovationLundbeckfond VenturesGlaxoSmithKlineMissing a round, or an investor who was in one? Tell us.
Spero Therapeutics's investors include SR One, National Science Foundation, RA Capital Management, Atlas Partner and Google Ventures, and 16 more on record.
Spero Therapeutics has raised $199M across 6 rounds since 2010. One round did not disclose an amount, so the total is a floor.
Spero Therapeutics's most recent round was a Debt of $105M in Jul 2026.
Its most recent round, $105M in Jul 2026, is also its largest on record.
Spero Therapeutics's first round on record, in Jan 2010, was backed by Atlas Partner.
Spero Therapeutics's latest named round is a Debt, in Jul 2026.
Spero Therapeutics is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
